Canopy Growth Posts 13% Revenue Growth in Q1 FY2027, Driven by MTL Cannabis Integration
Event summary
- Canopy Growth reported a 13% year-over-year increase in net revenue to $81.2M for Q1 FY2027, with contributions from all business segments.
- Cannabis net revenue grew by 14%, driven by the acquisition of MTL Cannabis and increased medical cannabis sales in Canada.
- Adjusted EBITDA loss improved by 59% to $3.2M, reflecting cost savings and revenue growth across segments.
- Storz & Bickel's net revenue rose by 6%, supported by product portfolio expansion and higher sales in non-core markets.
The big picture
Canopy Growth's Q1 FY2027 results highlight the strategic importance of its MTL Cannabis acquisition, which is driving supply improvements and revenue growth. The company's focus on cost management and gross margin expansion reflects broader industry trends toward profitability in the cannabis sector. However, regulatory challenges, particularly around medical cannabis reimbursement rates, remain a key risk.
What we're watching
- Integration Success
- Whether Canopy Growth can sustain the momentum from MTL Cannabis integration and realize further synergies in H2 FY2027.
- Regulatory Impact
- How the Canadian government's reduction in VAC reimbursement rates will affect medical cannabis revenue growth.
- Market Positioning
- The pace at which Canopy Growth can solidify its #6 ranking in Canada’s adult-use market and expand internationally.